Responses
Clinical/translational cancer immunotherapy
Original research
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
Compose a Response to This Article
Other responses
No responses have been published for this article.